Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications

키워드

참고문헌 (50)

1. Ather Muneer, "Staging Models in Bipolar Disorder: A Systematic Review of the Literature", Clinical Psychopharmacology and Neuroscience, 14(2), pp.117~130 (2016), 대한정신약물학회
2. Ather Muneer, "The Neurobiology of Bipolar Disorder: An Integrated Approach", 전남의대학술지, 52(1), pp.18~37 (2016), 의과학연구소
3. Cole AR, "Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia", FEBS J, 280, pp.5213~5227 (2013)
4. Uribe E, "Neuronal migration, apoptosis and bipolar disorder", Rev Psiquiatr Salud Ment, 5, pp.127~133 (2012)
5. Valvezan AJ, "GSK-3 and Wnt signaling in neurogenesis and bipolar disorder", Front Mol Neurosci, 5, pp.1~ (2012)
6. Golpich M, "Glycogen synthase kinase-3 beta(GSK-3)signaling : implications for Parkinson's disease", Pharmacol Res, 97, pp.16~26 (2015)
7. Beurel E, "Glycogen synthase kinase-3(GSK3): regulation, actions, and diseases", Pharmacol Ther, 148, pp.114~131 (2015)
8. Ka M, "mTOR regulates brain morphogenesis by mediating GSK3signaling", Development, 141, pp.4076~4086 (2014)
9. Durak O, "Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of β-catenin", Mol Psychiatry, 20, pp.388~397 (2015)
10. Jope RS, "Glycogen synthase kinase-3 in the etiology and treatment of mood disorders", Front Mol Neurosci, 4, pp.16~ (2011)
11. Rajkowska G, "Cell pathology in bipolar disorder", Bipolar Disord, 4, pp.105~116 (2002)
12. Karege F, "Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims", Biol Psychiatry, 61, pp.240~245 (2007)
13. Pandey GN, "Region-specific dysregulation of glycogen synthase kinase-3 and β-catenin in the postmortem brains of subjects with bipolar disorder and schizophrenia", Bipolar Disord, 17, pp.160~171 (2015)
14. Ren X, "Altered Wnt signalling in the teenage suicide brain : focus on glycogen synthase kinase-3β and β-catenin", Int J Neuropsychopharmacol, 16, pp.945~955 (2013)
15. Polter A, "Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances", Neuropsychopharmacology, 35, pp.1761~1774 (2010)
16. Li X, "Regulation of glycogen synthase kinase-3 during bipolar mania treatment", Bipolar Disord, 12, pp.741~752 (2010)
17. de Sousa RT, "Lithium increases platelet serine-9phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes", J Psychiatr Res, 62, pp.78~83 (2015)
18. Saus E, "A haplotype of glycogen synthase kinase 3β is associated with early onset of unipolar major depression", Genes Brain Behav, 9, pp.799~807 (2010)
19. Matigian N, "Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway", Mol Psychiatry, 12, pp.815~825 (2007)
20. Willour VL, "A genome-wide association study of attempted suicide", Mol Psychiatry, 17, pp.433~444 (2012)
21. Winham SJ, "Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2", Mol Psychiatry, 19, pp.1010~1016 (2014)
22. O'Shea KS, "Neurodevelopmental origins of bipolar disorder : iPSC models", Mol Cell Neurosci, 73, pp.63~83 (2016)
23. Madison JM, "Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities", Mol Psychiatry, 20, pp.703~717 (2015)
24. Gould TD, "Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications", Expert Opin Ther Targets, 10, pp.377~392 (2006)
25. Machado-Vieira R, "The role of lithium in the treatment of bipolar disorder : convergent evidence for neurotrophic effects as a unifying hypothesis", Bipolar Disord, 11(Suppl 2), pp.92~109 (2009)
26. Ferensztajn-Rochowiak E, "The effect of lithium on hematopoietic, mesenchymal and neural stem cells", Pharmacol Rep, 68, pp.224~230 (2016)
27. Hussaini SM, "Wnt signaling in neuropsychiatric disorders : ties with adult hippocampal neurogenesis and behavior", Neurosci Biobehav Rev, 47, pp.369~383 (2014)
28. Ather Muneer, "Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers", PSYCHIATRY INVESTIGATION, 13(1), pp.18~33 (2016), 대한신경정신의학회[DOI]
29. Ajmone-Cat MA, "Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells", Brain Behav Immun, 55, pp.225~235 (2016)
30. Viswanath B, "Cellular models to study bipolar disorder : a systematic review", J Affect Disord, 184, pp.36~50 (2015)
31. Li X, "Glycogen synthase kinase-3 beta, mood stabilizers, and neuroprotection", Bipolar Disord, 4, pp.137~144 (2002)
32. Du J, "Synaptic plasticity in the pathophysiology and treatment of bipolar disorder", Curr Top Behav Neurosci, 5, pp.167~185 (2011)
33. Ochs SM, "Loss of neuronal GSK3β reduces dendritic spine stability and attenuates excitatory synaptic transmission via β-catenin", Mol Psychiatry, 20, pp.482~489 (2015)
34. Smillie KJ, "Akt", PKB controls the activitydependent bulk endocytosis of synaptic vesicles, 2012, pp.13, 1004~1011
35. Beurel E, "HDAC6 regulates LPS-tolerance in astrocytes", PLoS One, 6, pp.e25804~ (2011)
36. Kalkman HO, "Potential opposite roles of the extracellular signal-regulated kinase(ERK)pathway in autism spectrum and bipolar disorders", Neurosci Biobehav Rev, 36, pp.2206~2213 (2012)
37. Besing RC, "Circadian rhythmicity of active GSK3isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus", J Biol Rhythms, 30, pp.155~160 (2015)
38. Paul JR, "Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3", Neuroscience, 226, pp.1~9 (2012)
39. McCarthy MJ, "Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients", Transl Psychiatry, 3, pp.e318~ (2013)
40. O'Brien WT, "Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice", J Clin Invest, 121, pp.3756~3762 (2011)
41. Kozikowski AP, "Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice", ChemMedChem, 6, pp.1593~1602 (2011)
42. O'Leary OF, "Lithium-induced effects on adult hippocampal neurogenesis are topographically segregated along the dorso-ventral axis of stressed mice", Neuropharmacology, 62, pp.247~255 (2012)
43. Kao CY, "The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities", J Neurochem, 126, pp.4~18 (2013)
44. Zhou R, "Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers", Neuropsychopharmacology, 34, pp.1395~1405 (2009)
45. Kalinichev M, "Evidence for antimanic efficacy of glycogen synthase kinase-3(GSK3)inhibitors in a strain-specific model of acute mania", Int J Neuropsychopharmacol, 14, pp.1051~1067 (2011)
46. de Bartolomeis A, "Update on the mechanism of action of aripiprazole : translational insights into antipsychotic strategies beyond dopamine receptor antagonism", CNS Drugs, 29, pp.773~799 (2015)
47. Pilar-Cúellar F, "Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity", Curr Pharm Des, 20, pp.3776~3794 (2014)
48. Del'Guidice T, "FXR1P is a GSK3 substrate regulating mood and emotion processing", Proc Natl Acad Sci U S A, 112, pp.E4610~E4619 (2015)
49. Meffre D, "Wnt and lithium: a common destiny in the therapy of nervous system pathologies?", Cell Mol Life Sci, 71, pp.1123~1148 (2014)
50. Furlotti G, "Hit optimization of 5-substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides : potent glycogen synthase kinase-3(GSK-3)inhibitors with in vivo activity in model of mood disorders", J Med Chem, 58, pp.8920~8937 (2015)

관련 논문AI추천